BV |
Bevacizumab |
BCA |
Bicinchoninic Acid |
CL |
Chemiluminescence |
DCC |
N,N′-dicyclohexylcarbodimide |
DHE |
Dihydroethidium |
ECL |
Enhanced chemiluminescence |
EGFR |
Epidermal growth factor receptor |
ESR1 |
Estrogen receptor α |
FDA |
Food and drug administration |
HER2 |
Human epidermal receptor 2 |
mAb(s) |
Monoclonal antibody(ies) |
MTT |
Tetrazolium dye 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide |
PAGE |
Polyacrylamide gel electrophoresis |
PR |
Progesterone receptor |
ROS |
Reactive oxygen specieis |
Se |
Selenium |
Se-BV |
Selenobevacizumab |
Se-TZ |
Selenotrastuzumab |
THF |
Tetrahydrofuran |
TNBC |
Triple negative breast cancer |
TZ |
Trastuzumab |
VEGF |
Vascular endothelial growth factor |
VEGFR |
Vascular endothelial growth factor receptor |